Drug Switching in Active Relapsing Remitting MS
A switch to a second-line drug in a patient receiving first-line therapies likely will be effective at decreasing disease activity.
MS and Natalizumab: 3 New Findings
Three brand new studies shed light on use of natalizumab in relapsing-remitting multiple sclerosis.
Multiple Sclerosis and the Radiologically Isolated Syndrome
Do you have a patient with "radiologically isolated syndrome" -- and, if so, what do you tell your patient?
3 New Things About MS
Highlights of recent findings about multiple sclerosis are summarized in this slide show.
Double Duty: Blood Pressure Drug Also Eases MS
An FDA-approved drug for high blood pressure alleviates clinical symptoms of MS in mice, showing great promise for humans.
Stem Cells Top Drug Therapy in Severe MS
This treatment may be superior to current treatment for patients with severe multiple sclerosis that is not responding well to standard treatments.
H. Pylori Might Curb MS Risk in Women
A new study indicates that infection with Helicobacter pylori might lower the risk of multiple sclerosis, at least in women. Pharmaceutical products could provide a novel means of treatment.
Stratifying PML Risk in Multiple Sclerosis
The risk of progressive multifocal leukoencephalopathy in patients receiving Tysabri for MS is a concern about this otherwise extremely effective therapy.
Immunosuppression, Stem Cells Halt MS
HDIT/HCT could induce sustained remission and neurological improvements in patients with multiple sclerosis.
New Concept in MS: NEDA
No evidence of disease activity (NEDA) is a new concept developing in MS. The field is beginning to ask how well the new treatments are doing and whether can we ultimately shut down the disease.